Cargando…

Modelling NAFLD disease burden in four Asian regions—2019‐2030

BACKGROUND: Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) account for an increasing proportion of liver disease in the Asia‐Pacific region. Many areas in the region are experiencing epidemics of metabolic syndrome among rapidly ageing populations. AIMS: To estima...

Descripción completa

Detalles Bibliográficos
Autores principales:	Estes, Chris, Chan, Henry L. Y., Chien, Rong N., Chuang, Wan‐Long, Fung, James, Goh, George Boon-Bee, Hu, Tsung H., Huang, Jee‐Fu, Jang, Byoung K., Jun, Dae W., Kao, Jia H., Lee, Jin‐Woo, Lin, Han‐Chieh, Razavi‐Shearer, Kathryn, Seto, Wai‐Kay, Wong, Grace L. ‐H., Wong, Vincent W. ‐S., Razavi, Homie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Nafld Disease Burden in Asia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154715/ https://www.ncbi.nlm.nih.gov/pubmed/32133676 http://dx.doi.org/10.1111/apt.15673

Ejemplares similares

Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease
por: Schwimmer, J B, et al.
Publicado: (2013)

Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease
por: Shen, Feng, et al.
Publicado: (2015)

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
por: Munteanu, M., et al.
Publicado: (2016)

Nonalcoholic fatty liver disease burden: Australia, 2019–2030
por: Adams, Leon A, et al.
Publicado: (2020)

The impact of immigration on hepatitis B burden in the United States: a modelling study
por: Razavi-Shearer, Devin, et al.
Publicado: (2023)

Comorbidities of migraine: a user-friendly overview
por: Carolei, Antonio, et al.
Publicado: (2003)

The global burden of migraine
por: Lipton, Richard B., et al.
Publicado: (2003)

Epidemiology of migraine
por: Manzoni, Gian Camillo, et al.
Publicado: (2003)

Migraine and disability: WHO's work to measure functioning, disability and health and the Global Burden of Diseases Study
por: Leonardi, Matilde
Publicado: (2003)

Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
por: Müllhaupt, Beat, et al.
Publicado: (2018)

From Materia Medica to the Pharmacopoeia: Challenges of Writing the History of Drugs in India
por: Bhattacharya, Nandini
Publicado: (2016)

Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden
por: Hajarizadeh, Behzad, et al.
Publicado: (2016)

Grade III or Grade IV Hypertensive Retinopathy with Severely Elevated Blood Pressure
por: Henderson, Amanda D., et al.
Publicado: (2012)

Nonalcoholic fatty liver disease burden – Saudi Arabia and United Arab Emirates, 2017–2030
por: Alswat, Khalid, et al.
Publicado: (2018)

Cost-effectiveness modelling of birth and infant dose vaccination against hepatitis B virus in Ontario from 2020 to 2050
por: Biondi, Mia J., et al.
Publicado: (2023)

Manual of fish eggs and larvae from Asian mangrove waters /
por: Jeyaseelan, M. J. Prince
Publicado: (1998)

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
por: Estes, Chris, et al.
Publicado: (2017)

Modelling hepatitis B virus infection and impact of timely birth dose vaccine: A comparison of two simulation models
por: de Villiers, Margaret J., et al.
Publicado: (2020)

Controversies and consensus of neoadjuvant chemotherapy in soft-tissue sarcomas
por: Loong, Herbert H., et al.
Publicado: (2018)

INSTRUMENT TO ASSESS BURDEN ON CAREGIVERS OF CHRONIC MENTALLY ILL
por: Thara, R., et al.
Publicado: (1998)

Study of type 2 diabetes management among patients in a Macau primary care setting
por: Wong, In
Publicado: (2019)

Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030
por: Schaefer, Benedikt, et al.
Publicado: (2018)

Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)
por: Zarghamravanbakhsh, Paria, et al.
Publicado: (2021)

Coronary artery disease epidemic in Pakistan: more electrocardiographic evidence of ischaemia in women than in men
por: Jafar, T H, et al.
Publicado: (2008)

HCV infection prevalence in a population recruited at health centers in Jordan
por: Hamoudi, Waseem, et al.
Publicado: (2013)

Asian resorts = Complejos turísticos asiáticos = Complessi turistici in asia
por: Tan, Hock Beng, 1962-
Publicado: (2003)

Impact of COVID-19 on global HCV elimination efforts
por: Blach, Sarah, et al.
Publicado: (2021)

Asian perspectives on NAPCRG
por: Lee, Eng Sing, et al.
Publicado: (2022)

Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model — Tashkent, Uzbekistan, December 6, 2019–March 15, 2020
por: Dunn, Rick, et al.
Publicado: (2020)

Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]
por: Bernstein, David, et al.
Publicado: (2022)

Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non‐alcoholic fatty liver disease; the importance of an elevated mean platelet volume
por: Abeles, Robin D., et al.
Publicado: (2019)

Effects of SARS-CoV2 pandemic in a cohort of italian NAFLD patients
por: Stefanini, Bernardo, et al.
Publicado: (2022)

Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States
por: Razavi, Homie, et al.
Publicado: (2013)

Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID‐19
por: Blach, Sarah, et al.
Publicado: (2021)

The Payer License Agreement, or “Netflix model,” for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition
por: Matthews, David W., et al.
Publicado: (2022)

First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia
por: TSAI, Shih-Tzer, et al.
Publicado: (2011)

Asia Oriental : opciones de desarrollo
Publicado: (1984)

Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia
por: Kim, Chul-Hee, et al.
Publicado: (2012)

Investigation of the introduction of three times daily injections of Insulin Lispro Mixture-50 on an outpatient basis: Therapeutic effects of 12 months’ treatment with and without concomitant sulfonylurea
por: Suzuki, Katsunori, et al.
Publicado: (2012)

Eye care in South Asia, 1988–2018: developments, achievements and future challenges
por: Murthy, Gudlavalleti VS
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c2pdog99lreqotsasb3jl2etac